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DNMT3a and TET2 in adipocyte insulin sensitivity
Sneha Damal Villivalam, Jinse Kim and Sona Kang
Insulin resistance (IR) is a key pathogenic feature 
of type 2 diabetes and occurs in a wide array of other 
maladies including obesity, aging, cardiovascular disease, 
and certain types of cancer. It results from an intricate 
interaction between genetic make-up and environment, 
suggesting it’s orchestrated by epigenetic mechanisms. 
In fact, a plethora of studies have found that changes 
in DNA methylation are associated with metabolic 
dysregulation [1, 2], but methylation’s functional role is 
poorly understood. 
DNA methylation is an epigenetic mark involving 
the covalent transfer of a methyl group to the C-5 position 
(5mC) of cytosine by DNA methyltransferases (DNMTs). 
The initial finding that DNMT levels are significantly 
increased in diet-induced obesity and genetically obese 
ob/ob mice led us to postulate that it plays a large role 
in IR [3]. We found that DNMT3a, in particular, is both 
necessary and sufficient to mediate IR in cultured mouse 
and human adipocytes. Indeed, adipose-specific Dnmt3a-
knockout mice are protected from diet-induced IR and 
glucose intolerance, with no change in their body weight 
or composition. Through RNA-seq studies, we found that 
an important downstream target is Fgf21, which is known 
to facilitate glucose uptake in adipocytes. In patients with 
diabetes, DNA methylation at the FGF21 locus is elevated 
in association with decreased expression of FGF21 in 
adipose tissue. Importantly, FGF21 expression partially 
rescues Dnmt3a-mediated IR in vitro, indicating that it is 
helping mediate the effect of DNMT3a on IR.
DNMTs methylate DNA, but this methylation can 
be erased by the TET proteins (TET1, 2, and 3), which 
oxidize 5mC to hydroxymethylcytosine (5hmC), which is 
then converted to unmethylated cytosine (5C) through base 
excision repair (BER) and thymidine DNA glycosylase 
(TDG) [4]. Given the functional role of DNMT3a in the 
development of IR, we hypothesized that the TET proteins 
play a counter-regulatory role. Indeed, adipose expression 
of TET2 is significantly decreased in diet-induced IR [5], 
and TET2 gain-of-function promotes insulin sensitivity 
while loss-of-function is necessary for insulin sensitization 
of PPARγ agonist, Rosiglitazone (Rosi). TET2 is required 
for Rosi-dependent gene activation of certain PPARγ 
targets, which is accompanied by changes in the DNA 
demethylation profile at their promoter regions (Figure 
1). Furthermore, TET2 physically interacts with PPARγ 
to sustain PPARγ binding to target loci upon PPARγ 
activation with Rosi (Figure 1). Together, these studies 
suggest that TET2 facilitates the transcriptional activity 
and insulin-sensitizing efficacy of PPARγ. 
In line with these findings, Wu et al recently 
published work revealing a novel axis between TET2 and 
AMPK in the regulation of glucose homeostasis [6]. This 
study found that hyperglycemia destabilizes TET2 through 
inhibiting AMPK-mediated TET2 phosphorylation at 
Ser99, which leads to downregulation of global 5hmC 
levels in the blood of diabetic patients. Furthermore, 
hyperglycemia-promoted tumor growth was suppressed 
by TET2, and the anti-tumor effect of Metformin appears 
to require the AMPK-TET2-5hmC axis. Together, 
these studies suggest that TET2 is a critical epigenetic 
sensor/regulator of glucose in the cell. It will be of great 
importance to find out whether this regulatory loop can be 
found in adipose and other metabolic tissues in the context 
of obesity and diabetes.
Several important questions still remain: 1) Do 
DNMT3a and TET2 directly converge to regulate insulin 
sensitivity? They functionally oppose one another, but 
physical interaction between the two was not detectable 
by co-immunoprecipitation, and most of their gene 
targets do not overlap [3, 5]. 2) What is the in vivo role 
of TET2 in adipose and other tissues? Studies on TET2 
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Figure 1: Proposed model of TET2 as a regulator of 
PPARγ-dependent transcription in adipocytes. TET2 
physically interacts with PPARγ to sustain PPARγ binding 
at PPARγ responsive elements (PPREs) and to facilitate the 
transcriptional activation of PPARγ in response to Rosiglitazone 
(Rosi). TET2 causes demethylation at the promoter regions 
of some PPARγ target genes such as Adipoq in a site-specific 
manner, which can affect insulin sensitivity. Based upon recent 
finding by Wu et al, it is postulated that AMPK may act as an 
upstream of TET2 in adipocytes (Open circle; demethylated 
CpG).
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were conducted using cultured adipocyte models, thus 
physiological validation using tissue-specific knockout 
and transgenic mouse models will be critical. It will be 
intriguing to investigate whether adipose-specific Tet2-
knockout mice are refractory to Rosi-driven insulin 
sensitization. 3) How do DNMT3a and TET2 affect 
the adipose epigenome? Investigation into the DNA 
methylation activity of DNMT3a and TET2 has been 
limited to the promoter regions of key target genes, but 
gene bodies and enhancers may also be methylated, 
having different impacts on gene regulation depending on 
the function of the region and CpG density. To gain a more 
comprehensive understanding, global DNA methylation 
profiling studies will be necessary, ideally using in vivo 
models. 
Answering these questions will lead to a more 
detailed understanding of the mechanisms of DNMT3a 
and TET2, which may lead to identifying novel targets for 
the treatment of IR and relevant human diseases.
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